The appearance of multidrug resistance during treatment of various malignancies with anticancer agents must be detected as soon as possible. In an attempt to achieve this, we first established an adriamycin-resistant cell line, K562 (K562/ ADM), from its parental line, K562 , and finally obtained several murine monoclonal antibodies (MAbs) reactive with K562/ADM by immunising mice with these cells and hybridising the spleen cells from these animals with murine myeloma cells Hamada et al., 1989) . Of these MAbs, MRK 16 recognised Mr 170,000-180,000 P-glycoprotein, while another, MRK 20, recognised an Mr 85,000 protein Hamada et al., 1989) . Both proteins seem to be associated with the mechanism of multidrug resistance Sugawara et al., 1988b) .
In the present study, we utilised these two MAbs, MRK 16 and MRK 20, to investigate their potential usefulness for the detection of multidrug-resistant cancer cells during treatment of leukaemia and malignant lymphoma.
Materials and methods

Patients
The subjects of this study were 31 patients referred to the Department of Internal Medicine, Institute of Medical Science, University of Tokyo, for evaluation and therapy of haematological malignancies.
Flow cytometry
Whole peripheral blood was reacted with MRK 16 (5 ytg ml-'), MRK 20 (5 jig ml-') or non-immune mouse serum (Sigma, 5 . The MNC consisted mainly of lymphocytes and monocytes as assessed by the immunofluorescence antibody technique. For immunocytochemistry, the ABC-PO method was utilised (Hsu et al., 1981; Sugawara et al., 1988b Laemmli's method (Laemmli, 1970) . Briefly, the cells were solubilised with 500jil of cell lysis buffer containing 1% Triton Xl00, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 0.15 M NaCI, 50 mM Tris-HCI (pH 7.4) and 2 mM phenylmethylsulphonyl fluoride (PMSF). After the solubilised proteins had been subjected to SDS-PAGE, they were transferred on to nitrocellulose membrane filters. Thereafter, immunochemistry (ABC-PO method) was carried out for detection of the protein (Hsu et al., 1981) . 
Results
Flow cytometric and immunocytometric ftatures
Discussion
Our present data revealed several interesting features. First, P-glycoprotein was detected in haematological malignancies. Tsuruo et al. (1987) and Ma et al. (1987) have also reported similar findings. It was clearly apparent that expression of P-glycoprotein was closely related to the prior administration of anticancer drugs. Although we determined the total amounts of anticancer drugs used, we were unable to detect exactly when during the treatment P-glycoprotein appeared in the cells. On the other hand, the M, 85,000 protein recognised by MRK 20
MAb was detected both before and during treatment of haematological malignancies. It has been reported recently that an Mr 85,000 protein is closely associated with resistance to adriamycin (Hamada et al., 1989; Sugawara et al., 1988b ). We had also been able to confirm the appearance of the M, 85,000 protein during treatment of K 562 cells with adriamycin (our unpublished data). The complete amino acid sequence of the Mr 85,000 protein is still unknown, but it appears to be of some importance in view of its high frequency of detection (approx. 60%). The second important point is that some haematological malignancies appear to show intrinsic drug resistance, as indicated in Table I . It has already been suggested that intrinsic drug resistance mechanisms exist in some solid tumours such as kidney, lung and breast cancer (Fojo et al., 1987; Sugawara et al., 1988a) . Expression of Mr 85,000 protein appears to be much more closely associated with intrinsic drug resistance in haematological malignancies. As we were unable to examine whether MRK 16-and MRK 20-positive cells are resistant to certain anticancer drugs due to paucity of the cells, this aspect awaits further study. However, both MRK 16-and MRK 20- negative leukaemic cells were sensitive to adriamycin and vincristine in terms of IC50, in comparison with K 562 cells (our unpublished data).
Finally, from our present data, it is suggested that MRK 16 and MRK 20 MAbs may have two potentially useful clinical applications. One is that the MAbs, either by themselves or in combination with toxins or radioisotopes, could be used for selective ex vivo killing of cancer cells containing high levels of P-glycoprotein. The other is that the MAbs could be useful for detecting the degree of multidrug resistance in various types of malignancy in vitro. 
